CelLBxHealth plc (AIM:CLBX)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 10.23M |
| Revenue (ttm) | 2.62M |
| Net Income (ttm) | -15.78M |
| Shares Out | 1.14B |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 647,832 |
| Average Volume | 2,168,037 |
| Open | 1.000 |
| Previous Close | 0.950 |
| Day's Range | 0.900 - 1.000 |
| 52-Week Range | 0.850 - 11.440 |
| Beta | 0.27 |
| RSI | 37.64 |
| Earnings Date | Jun 1, 2026 |
About CelLBxHealth
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytic... [Read more]
Financial Performance
In 2024, CelLBxHealth's revenue was 2.86 million, an increase of 30.92% compared to the previous year's 2.19 million. Losses were -14.23 million, -29.34% less than in 2023.
Financial StatementsNews
CelLBxHealth Transcript: Investor Update
A new leadership team is driving a focused commercialization strategy, restructuring operations, and targeting profitability by 2028. Strategic partnerships and a narrowed market focus aim to capitalize on the growing need for circulating tumor cell diagnostics, with significant cost reductions and value inflection points expected in the next 12-18 months.
CelLBxHealth Earnings Call Transcript: H1 2025
Major commercialization progress with pharma and medtech, including a new Myriad Genetics partnership, was offset by revenue declines due to market headwinds. Cost controls reduced losses, and the cash runway extends into Q1 2026. NHS engagement and new clinical evidence support future growth.
CelLBxHealth Earnings Call Transcript: H2 2024
2024 saw 31% revenue growth, major pharma contracts, and a breakthrough in DNA dual analysis, despite market headwinds and funding delays. The pipeline is strong, with new medtech and pharma opportunities, and a cash runway into Q1 2026.
CelLBxHealth Transcript: Emerging Growth Conference 79
A novel blood-based technology enables real-time, comprehensive cancer profiling by isolating living tumor cells, supporting early diagnosis, treatment selection, and remission monitoring. Strategic pharma partnerships and high-margin product and service revenues position the company for significant growth.
CelLBxHealth Earnings Call Transcript: H1 2024
Strong H1 progress in pharma services with three major contracts secured, but product sales lag due to regulatory and funding headwinds. Revenue guidance for 2024 is lowered, with a strategic pivot to large pharma expected to drive future growth.
CelLBxHealth Transcript: Investor Update
CelLBxHealth Earnings Call Transcript: H1 2023
CelLBxHealth Earnings Call Transcript: H2 2022
CelLBxHealth Earnings Call Transcript: H1 2022
CelLBxHealth Transcript: AGM 2022
CelLBxHealth Transcript: FDA Announcement
CelLBxHealth Earnings Call Transcript: H2 2021
CelLBxHealth Earnings Call Transcript: H1 2021
Angle PLC Announces Parsortix study uncovers targets in TNBC patients
Parsortix system harvests intact CTCs for whole genomic sequencing identifying multiple druggable targets Study demonstrates ctDNA and CTCs can both be analysed using the same blood sample GUILDFORD, ...